BioFocus and CHDI Foundation Enter new Five-Year Collaboration for Huntington’s Disease Therapeutics
News Apr 30, 2010
BioFocus and CHDI Foundation, Inc., a non-profit virtual biotech pursuing therapies for Huntington’s disease, announced a new five-year collaboration focused on discovering novel drugs for Huntington’s disease. BioFocus will perform the research and is eligible to receive US$41 million (€31 million) in research fees during the five-year collaboration.
BioFocus will apply its full range of integrated drug discovery services for this program. Integrated biology and chemistry capabilities will be supported by BioFocus’ expertise in complex primary neuronal assay development, high-content screening, fragment-based screening, computational chemistry, ADME/PK and protein crystallography. The new agreement continues and expands the collaboration started in August 2005.
“Having collaborated with CHDI since 2005 in therapeutic target discovery, we are eager to continue working together to develop novel therapies for Huntington's disease and meet this urgent medical need,” said Onno van de Stolpe, CEO of Galapagos. “We are confident that the next five years of this long-standing relationship with CHDI will be as productive as the first five.”
“BioFocus has delivered expert technologies and experienced staff to therapeutic target and drug discovery research in the fight against Huntington’s disease,” said Ignacio Munoz-Sanjuan, Vice-President, Biology at CHDI. “This has encouraged us to extend and expand the collaboration, with the ultimate goal of finding disease-modifying treatments for Huntington’s.”
New Studies Demonstrate Risk Reduction Potential of Heat-Not-Burn Tobacco Products and e-CigarettesNews
Data presented at the Society of Toxicology Annual Meeting (SOT) have demonstrated the potential of two different heat-not-burn tobacco products and e-cigarettes to reduce the risk of smoking-related diseases, in comparison to continued use of conventional cigarettes.READ MORE
Exposure to Low Levels of BPA during Pregnancy Can Lead to Altered Brain DevelopmentNews
New research in mice provides an explanation for how exposure to the widely used chemical bisphenol A (BPA) during pregnancy, even at levels lower than the regulated “safe” human exposure level, can lead to altered brain development and behavior later in life.READ MORE
Moving Toward a Future Free of Drug-Induced Hearing LossNews
A new special publication orchestrated by five of the nation's leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents - how it occurs, how to treat it, and how to prevent it.READ MORE